Aflac Incorporated (NYSE:AFL) Holdings Decreased by Kovack Advisors Inc.

Kovack Advisors Inc. lowered its holdings in Aflac Incorporated (NYSE:AFL) by 34.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,533 shares of the financial services provider’s stock after selling 1,824 shares during the period. Kovack Advisors Inc.’s holdings in Aflac were worth $395,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Y.D. More Investments Ltd acquired a new stake in shares of Aflac in the second quarter valued at approximately $25,000. Covestor Ltd increased its position in Aflac by 41.8% in the 3rd quarter. Covestor Ltd now owns 363 shares of the financial services provider’s stock valued at $41,000 after acquiring an additional 107 shares during the period. Kennebec Savings Bank bought a new stake in Aflac during the 3rd quarter valued at $45,000. Cedar Wealth Management LLC acquired a new position in Aflac during the 1st quarter worth $50,000. Finally, Catalyst Capital Advisors LLC bought a new position in shares of Aflac in the third quarter worth $51,000. 67.44% of the stock is currently owned by institutional investors and hedge funds.

Aflac Stock Down 0.7 %

NYSE AFL opened at $109.69 on Friday. Aflac Incorporated has a twelve month low of $75.07 and a twelve month high of $115.50. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.08 and a current ratio of 0.08. The stock has a market cap of $60.94 billion, a PE ratio of 16.52, a PEG ratio of 2.13 and a beta of 0.96. The firm has a 50-day simple moving average of $110.36 and a 200 day simple moving average of $99.22.

Aflac (NYSE:AFL) last announced its quarterly earnings data on Wednesday, October 30th. The financial services provider reported $2.16 EPS for the quarter, topping analysts’ consensus estimates of $1.69 by $0.47. The company had revenue of $2.95 billion during the quarter, compared to the consensus estimate of $4.30 billion. Aflac had a return on equity of 16.34% and a net margin of 22.02%. The company’s quarterly revenue was down 40.4% on a year-over-year basis. During the same quarter last year, the company earned $1.84 EPS. On average, research analysts forecast that Aflac Incorporated will post 7.22 EPS for the current year.

Aflac Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Wednesday, November 20th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.82%. The ex-dividend date of this dividend is Wednesday, November 20th. Aflac’s dividend payout ratio is 30.12%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Piper Sandler boosted their price objective on Aflac from $114.00 to $122.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 2nd. Evercore ISI upped their price target on Aflac from $84.00 to $90.00 and gave the company an “underperform” rating in a research report on Thursday, September 26th. Citigroup increased their target price on shares of Aflac from $84.00 to $93.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 23rd. JPMorgan Chase & Co. lifted their price target on Aflac from $85.00 to $90.00 and gave the company a “neutral” rating in a report on Thursday, October 3rd. Finally, Barclays began coverage on shares of Aflac in a report on Wednesday, September 4th. They issued an “underweight” rating and a $96.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Aflac currently has an average rating of “Hold” and an average price target of $97.93.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.